Expression of the miR-221/222 cluster can safeguards transplanted HSC from loss of lymphoid-myeloid multipotency

Main Article Content

Fritz Melchers Peter K. Jani


A microRNA cluster, miR‑221/222, is expressed in quiescent and activated HSC of mice. The expressions of fos and jun, hence AP-1, and a collection of other immediate early genes (IEG), are up-regulated in miR-221/222-deficient HSC. Social stress and HSC transplantation induces comparable up-regulation of IEGs. Stress, as well as miR-221/222-deficiency leads to decreases in the numbers of quiescent HSC and increases in the number of activated hematopoietic (MPP2-4) progenitors, as well as numbers of progenitors of emergency granulopoiesis. Serial transplantations of miR-221/222-deficient HSC generated HSC in the recipient bone marrow, prematurely lose their lymphoid repopulation capacities – normally a sign of aged HSC. Consequently, enforced expression of miR-221/222 should preserve and enhance lymphoid potency of HSC. These results suggest that the expression of miR-221/222 genes themselves and target genes of miR-221/222 in HSC should improve HSC performance in bone marrow niches and their lymphoid development in the transplanted host. Since the miR-221 and -222 genes are also expressed in human HSC, it is likely, that these new targets should be applicable to the improvement of human bone marrow transplantation.

Keywords: miR-221/222 cluster, lymphoid-myeloid multipotency

Article Details

How to Cite
MELCHERS, Fritz; JANI, Peter K.. Expression of the miR-221/222 cluster can safeguards transplanted HSC from loss of lymphoid-myeloid multipotency. Medical Research Archives, [S.l.], v. 12, n. 1, jan. 2024. ISSN 2375-1924. Available at: <>. Date accessed: 03 mar. 2024. doi:
Research Articles


1. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood. 1998;91(7):2588-2600.

2. Ogonek J, Kralj Juric M, Ghimire S, et al. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2016;7:507.

3. van den Brink MR, Velardi E, Perales MA. Immune reconstitution following stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015;2015:215-219.

4. Halliwell B. Cell culture, oxidative stress, and antioxidants: avoiding pitfalls. Biomed J. 2014;37(3):99-105.

5. Lan Q, Mercurius KO, Davies PF. Stimulation of transcription factors NF kappa B and AP1 in endothelial cells subjected to shear stress. Biochem Biophys Res Commun. 1994;201(2):950-956.

6. McKim DB, Yin W, Wang Y, Cole SW, Godbout JP, Sheridan JF. Social Stress Mobilizes Hematopoietic Stem Cells to Establish Persistent Splenic Myelopoiesis. Cell Rep. 2018;25(9):2552-2562 e2553.

7. Carrelha J, Meng Y, Kettyle LM, et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature. 2018;554(7690):106-111.

8. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 2011;11(5):330-342.

9. Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. 2005;26(1):56-64.

10. Teshima T, Reddy P, Lowler KP, et al. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease. Blood. 2002;99(5):1825-1832.

11. Buza-Vidas N, Cheng M, Duarte S, Nozad H, Jacobsen SE, Sitnicka E. Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy. Blood. 2007;110(1):424-432.

12. Hassan M, Ulezko Antonova A, Li JM, et al. Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes. Biol Blood Marrow Transplant. 2019;25(6):1075-1084.

13. Jani PK, Petkau G, Kawano Y, et al. The miR-221/222 cluster regulates hematopoietic stem cell quiescence and multipotency by suppressing both Fos/AP-1/IEG pathway activation and stress-like differentiation to granulocytes. PLoS Biol. 2023; 21(11):e3002015.

14. Bissels U, Wild S, Tomiuk S, et al. Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells. Stem Cells. 2011;29(5):847-857.

15. sBaldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature. 2010;465(7299):793-797.

16. Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005;102(26):9194-9199.

17. Jang Y, Kim YS, Wielgosz MM, et al. Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy. Gene Ther. 2020;27(12):545-556.

18. Li C, Lieber A. Adenovirus vectors in hematopoietic stem cell genome editing. FEBS Lett. 2019;593(24):3623-3648.

19. Gossen M. BH. Tetracyclines in the control of gene expression in eukaryotes. Basel: Birkhäuser Verlag; 2001.

20. Das AT, Tenenbaum L, Berkhout B. Tet-On Systems For Doxycycline-inducible Gene Expression. Curr Gene Ther. 2016;16(3):156-167.

21. Knoll M, Simmons S, Bouquet C, Grun JR, Melchers F. miR-221 redirects precursor B cells to the BM and regulates their residence. Eur J Immunol. 2013;43(9):2497-2506.

22. Petkau G, Kawano Y, Wolf I, Knoll M, Melchers F. MiR221 promotes precursor B-cell retention in the bone marrow by amplifying the PI3K-signaling pathway in mice. Eur J Immunol. 2018;48(6):975-989.

23. Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833-1840.

24. Alameh MG, Tombacz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021; 54(12):2877-2892 e2877.